Prosecution Insights
Prosecution Insights
29 pending office actions • 25 clients • 28 examiners • 23 art units • 0 of 29 (0%) have an AI response strategy ready • 38 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 13 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 13 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (3%) |
| §103 only | 16 (55%) |
| §102 only | 3 (10%) |
| §112 only | 4 (14%) |
| Double-patenting only | 2 (7%) |
| Double-patenting + other | 2 (7%) |
| No statute on record | 1 (3%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MIKNIS, ZACHARY J | 2 | 68.4% | +32.3% |
| NGUYEN, KATHLEEN V | 1 | 66.3% | +26.7% |
| HELM, CARALYNNE E | 1 | 28.8% | +49.6% |
| JENKINS, JERMAINE L | 1 | 88.1% | +8.0% |
| DIVIESTI, KARLA ISOBEL | 1 | 4.3% | +25.0% |
| PIPIC, ALMA | 1 | 54.2% | +55.7% |
| GORDON, MELENIE LEE | 1 | 22.9% | +46.1% |
| AMICK, THOMAS RUSSE | 1 | 72.8% | +31.0% |
| HAGHIGHATIAN, MINA | 1 | 45.8% | +39.7% |
| PRAKASH, SUBBALAKSHMI | 1 | 44.9% | +37.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18782209 | HIGH PERFORMANCE LIQUID CHROMATOGRAPHY PUMP, AND LIQUID CHROMATOGRAPHY SYSTEM COMPRISING SAME | JENKINS, JERMAINE L | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18822019 | Metal Oxide Compounds with Enhanced Reactivity | HELM, CARALYNNE E | 8d overdue |
| 18570202 | USE OF LACTOBACILLUS FERMENTUM STRAIN AND REGULATORY T CELLS FOR COMBINATION THERAPY FOR PREVENTION OR TREATMENT OF METABOLIC DISEASES | GORDON, MELENIE LEE | 41d |
| 18661648 | PREPARATION AND UTILIZATION OF MICROBIAL-BASED EGG FLUID SUBSTITUTE AND MILK SUBSTITUTE | DIVIESTI, KARLA ISOBEL | — |
| 18562322 | COMPOSITION FOR COMBINATION THERAPY COMPRISING GROWTH DIFFERENTIATION FACTOR-15 VARIANT AND GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST | MIKNIS, ZACHARY J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18559381 | COMPOSITION FOR NK CELL CRYOPRESERVATION AND CRYOPRESERVATION FORMULATION COMPRISING SAME | AMICK, THOMAS RUSSE | 31d overdue |
| 18488375 | PHARMACY COMPOUNDED PRESCRIPTION COMPOSITIONS FOR HAIR GROWTH | HAGHIGHATIAN, MINA | 31d overdue |
| 18822019 | Metal Oxide Compounds with Enhanced Reactivity | HELM, CARALYNNE E | 8d overdue |
| 18570202 | USE OF LACTOBACILLUS FERMENTUM STRAIN AND REGULATORY T CELLS FOR COMBINATION THERAPY FOR PREVENTION OR TREATMENT OF METABOLIC DISEASES | GORDON, MELENIE LEE | 41d |
| 18852449 | MEASURING DEVICE BASED ON A COMBINATION OF OPTICAL 2D AND 3D IMAGE CAPTURING METHODS | NGUYEN, KATHLEEN V | — |
| 18661648 | PREPARATION AND UTILIZATION OF MICROBIAL-BASED EGG FLUID SUBSTITUTE AND MILK SUBSTITUTE | DIVIESTI, KARLA ISOBEL | — |
| 18571238 | LIPID NANOPARTICLES AND METHOD FOR PREPARING SAME | PIPIC, ALMA | — |
| 18562322 | COMPOSITION FOR COMBINATION THERAPY COMPRISING GROWTH DIFFERENTIATION FACTOR-15 VARIANT AND GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST | MIKNIS, ZACHARY J | — |
| Art Unit | Apps |
|---|---|
| 1617 | 2 |
| 1658 | 2 |
| 1615 | 1 |
| 1792 | 1 |
| 1651 | 1 |
| 1638 | 1 |
| 1616 | 1 |
| 1793 | 1 |
| 1635 | 1 |
| 1641 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18852449 | MEASURING DEVICE BASED ON A COMBINATION OF OPTICAL 2D AND 3D IMAGE CAPTURING METHODS | BESI Switzerland AG | NGUYEN, KATHLEEN V | §103 | Non-Final OA | — | Pending | May 09, 2025 | |
| 18822019 | Metal Oxide Compounds with Enhanced Reactivity | Nanoionix, LLC | HELM, CARALYNNE E | 1615 | §103 | Non-Final OA | 8d overdue | Pending | Aug 30, 2024 |
| 18782209 | HIGH PERFORMANCE LIQUID CHROMATOGRAPHY PUMP, AND LIQUID CHROMATOGRAPHY SYSTEM COMPRISING SAME | Practichem LLC | JENKINS, JERMAINE L | §112 | Non-Final OA | — | Pending | Jul 24, 2024 | |
| 18661648 | PREPARATION AND UTILIZATION OF MICROBIAL-BASED EGG FLUID SUBSTITUTE AND MILK SUBSTITUTE | Korea Advanced Institute Of Science And Technology | DIVIESTI, KARLA ISOBEL | 1792 | §103 | Non-Final OA | — | Pending | May 12, 2024 |
| 18571238 | LIPID NANOPARTICLES AND METHOD FOR PREPARING SAME | Therna Therapeutics | PIPIC, ALMA | 1617 | §103 | Final Rejection | — | Pending | Dec 17, 2023 |
| 18570202 | USE OF LACTOBACILLUS FERMENTUM STRAIN AND REGULATORY T CELLS FOR COMBINATION THERAPY FOR PREVENTION OR TREATMENT OF METABOLIC DISEASES | Gi Biome | GORDON, MELENIE LEE | 1651 | §102 | Non-Final OA | 41d | Pending | Dec 14, 2023 |
| 18562322 | COMPOSITION FOR COMBINATION THERAPY COMPRISING GROWTH DIFFERENTIATION FACTOR-15 VARIANT AND GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST | Yuhan Corporation | MIKNIS, ZACHARY J | 1658 | §101 | Non-Final OA | — | Pending | Nov 19, 2023 |
| 18513613 | COMPOSITION FOR PREVENTING OR TREATING NON-ALCOHOLIC FATTY LIVER DISEASE OR NON-ALCOHOLIC STEATOHEPATITIS COMPRISING GROWTH DIFFERENTIATION FACTOR-15 VARIANT | Yuhan Corporation | MIKNIS, ZACHARY J | DP | Non-Final OA | — | Pending | Nov 19, 2023 | |
| 18559381 | COMPOSITION FOR NK CELL CRYOPRESERVATION AND CRYOPRESERVATION FORMULATION COMPRISING SAME | Gi Cell, Inc. | AMICK, THOMAS RUSSE | 1638 | §102 | Non-Final OA | 31d overdue | Pending | Nov 07, 2023 |
| 18488375 | PHARMACY COMPOUNDED PRESCRIPTION COMPOSITIONS FOR HAIR GROWTH | Remi Medical, LLC | HAGHIGHATIAN, MINA | 1616 | §103 | Non-Final OA | 31d overdue | Pending | Oct 17, 2023 |
| 18548248 | FOOD HAVING IMPROVED FLAVOR, NUTRITION, AND COLOR AND PREPARATION METHOD THEREFOR | Korea Advanced Institute Of Science And Technology | PRAKASH, SUBBALAKSHMI | 1793 | §112 | Final Rejection | — | Pending | Aug 29, 2023 |
| 18261882 | COMPOSITION FOR ALLEVIATING HAIR GRAYING, PROMOTING HAIR GROWTH AND/OR PREVENTING OR ALLEVIATING HAIR LOSS, COMPRISING DOUBLE-STRANDED MIRNA AS ACTIVE INGREDIENT | Sirnagen Therapeutics Corporation | YU, DAVID TUYANG | 1635 | §103 | Non-Final OA | — | Pending | Jul 18, 2023 |
| 18260308 | ANTI-FGFR3 ANTIBODY AND USE THEREOF | Aimed Bio Inc. | TAYLOR, LIA ELAN | 1641 | DPOther | Non-Final OA | — | Pending | Jul 03, 2023 |
| 18254859 | RECOMBINANT MICROORGANISM HAVING IMPROVED ABILITY TO PRODUCE RECOMBINANT SILK PROTEIN AND METHOD FOR PRODUCING HIGH-MOLECULAR-WEIGHT RECOMBINANT SILK PROTEIN BY USING SAME | Medicosbiotech, Inc. | TSAY, MARSHA M | 1656 | §103 | Final Rejection | 84d | Pending | May 28, 2023 |
| 18253582 | METHOD FOR ISOLATING NUCLEIC ACID USING BINDING BUFFER INCLUDING COMPOUND HAVING LOW OR INTERMEDIATE DIELECTRIC CONSTANT | BIONEER CORPORATION | BUCHANAN, BAILEY CHEYENNE | 1682 | §103 | Non-Final OA | 66d overdue | Pending | May 18, 2023 |
| 18252598 | LOW NI CONTENT AUSTENITIC STAINLESS STEEL WITH HIGH STRENGTH / DUCTILITY PROPERTIES | Fundación Tecnalia Research & Innovation | SU, XIAOWEI | 1733 | §103 | Final Rejection | — | Pending | May 11, 2023 |
| 18246193 | COMPOSITION FOR PREVENTING OR TREATING DEMENTIA, CONTAINING PEPTIDE NUCLEIC ACID COMPLEX AS ACTIVE INGREDIENT | Seasun Therapeutics | CHERNYSHEV, OLGA N | 1675 | §112 | Non-Final OA | 4d overdue | Pending | Mar 22, 2023 |
| 18183489 | ALKYL-LINKED POROUS PORPHYRIN POLYMER, AND METHOD OF SEPARATING GAS AND METHOD OF RECOVERING VALUABLE METAL USING SAME | Korea Advanced Institute Of Science And Technology | CHEN, PO-CHIH | 1621 | §112 | Final Rejection | 56d overdue | Pending | Mar 14, 2023 |
| 18044365 | CORONAVIRUS-DERIVED RECEPTOR-BINDING DOMAIN VARIANT HAVING REDUCED ACE2-BINDING AFFINITY AND VACCINE COMPOSITION COMPRISING THE SAME | Gi Cell, Inc. | REDDIG, PETER J | 1646 | §103 | Non-Final OA | 99d overdue | Pending | Mar 07, 2023 |
| 18164387 | DEEP LEARNING BASED METHOD FOR DIAGNOSING AND PREDICTING CANCER TYPE USING CHARACTERISTICS OF CELL-FREE NUCLEIC ACID | Gc Genome Corporation | LIN, JERRY | DP | Non-Final OA | — | Pending | Feb 03, 2023 | |
| 17907432 | COMPOSITION USING URINE SAMPLE FOR DIAGNOSIS OF KIDNEY DISEASE | Soonchunhyang University Industry Academy Cooperation Foundation | EVANS, CHRISTOPHER RYAN | 1677 | §103 | Non-Final OA | — | Pending | Sep 27, 2022 |
| 17620712 | PHARMACEUTICAL FORMULATION OF NON-ACTIVATED POLYPEPTIDE TRP | Met Life Sciences Co., Ltd. | MARTINEZ, TARA L | 1654 | DPOther | Non-Final OA | — | Pending | Jun 29, 2022 |
| 17784970 | PRETREATMENT METHOD FOR UTILIZATION OF COAL ASH LANDFILLED IN ASH PONDS | National Institute Of Environmental Research | KUMAR, KALYANAVENKA K | 3653 | §103 | Non-Final OA | — | Pending | Jun 13, 2022 |
| 17781669 | PHARMACEUTICAL COMPOSITION COMPRISING SMALL OCTOPUS-DERIVED PEPTIDE FOR TREATMENT OF INFLAMMATORY DISEASE | National Marine Biodiversity Institute Of Korea | HIBBERT, CATHERINE S | 1658 | Other | Final Rejection | 1d overdue | Pending | Jun 01, 2022 |
| 17692111 | NOVEL N-ACYLUREA DERIVATIVE AND COMPOSITION COMPRISING SAME FOR PREVENTION OR TREATMENT OF CARDIOVASCULAR DISEASE | Kyungpook National University Industry- Academic Cooperation Foundation | AGUIRRE, AMANDA L | 1626 | §102 | Final Rejection | — | Pending | Mar 10, 2022 |
| 17620183 | METHOD FOR INCREASING CONTENT OF NK CELLS USING CULTURE MEDIUM OF IMMUNE CELLS OF HEALTHY PERSON | Jeong Chan Ra | BATES, KEENAN ALEXANDER | 1631 | §103 | Final Rejection | 60d overdue | Pending | Dec 17, 2021 |
| 17598199 | SPRAY-DRIED POWDERS | Zoomessence, Inc. | GWARTNEY, ELIZABETH A | 1759 | §103 | Final Rejection | 98d overdue | Pending | Sep 24, 2021 |
| 16759281 | COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, CONTAINING MARINE FUNGUS PENICILLIUM SP. SF-5859-DERIVED CURVULARIN-TYPE METABOLITES | Korea Insititute Of Ocean Science And Technology | SIMMONS, CHRIS E | 1622 | §103 | Non-Final OA | — | Pending | Apr 24, 2020 |
| 16623167 | INTEGRAL BIOMATERIAL FOR REGENERATION OF BONE TISSUE AND FABRICATION METHOD THEREFOR | Seoul National University R&Db Foundation | HAGOPIAN, CASEY SHEA | 1617 | §103 | Non-Final OA | 30d overdue | Pending | Dec 16, 2019 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial